A formulation and method of micelle production including the steps of dissolving amphiphilic block copolymers in a mixed solvent comprising water and a non-aqueous co-solvent, conducting a single-step dialysis against water or saline in order to produce monodisperse kinetically frozen polymer micelles with DLS size polydispersities less than about 0.2 in aqueous conditions or conducting an evaporation process for removal of non-aqueous solvent content in order to produce monodisperse kinetically frozen polymer micelles with DLS size polydispersities less than about 0.2 in aqueous conditions.

Described herein are methods for preventing non-insulted cell damage during a subject's exposure to radiation. In some embodiments, the method can include administering an amount of poloxamer 188 or a pharmaceutical formulation thereof to a subject prior to exposure to an insult.

The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel when a polymer in the formulation exceeds a threshold level (optionally a pre-determined threshold level) for a property of the polymer of the formulation, which threshold level may be for example, a physical (e.g., temperature), chemical (e.g., pH), or temporal threshold level following contact with the affected tissue. In certain aspects, a combination of properties, such as a combination of physical (e.g., temperature), chemical (e.g., pH), or temporal threshold levels determines when the polymer in the formulation transitions from a liquid to a gel. Methods of using such compositions are also provided.

The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel when a polymer in the formulation exceeds a threshold level (optionally a pre-determined threshold level) for a property of the polymer of the formulation, which threshold level may be for example, a physical (e.g., temperature), chemical (e.g., pH), or temporal threshold level following contact with the affected tissue. In certain aspects, a combination of properties, such as a combination of physical (e.g., temperature), chemical (e.g., pH), or temporal threshold levels determines when the polymer in the formulation transitions from a liquid to a gel. Methods of using such compositions are also provided.

The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel when a polymer in the formulation exceeds a threshold level (optionally a pre-determined threshold level) for a property of the polymer of the formulation, which threshold level may be for example, a physical (e.g., temperature), chemical (e.g., pH), or temporal threshold level following contact with the affected tissue. In certain aspects, a combination of properties, such as a combination of physical (e.g., temperature), chemical (e.g., pH), or temporal threshold levels determines when the polymer in the formulation transitions from a liquid to a gel. Methods of using such compositions are also provided.

The present invention refers to a pharmaceutical formulation for injection comprising fluorescent nanoparticles as in vivo diagnostics. The present invention relates to an injectable pharmaceutical formulation for human medicine and/or veterinary use, comprising 17% to 20% per weight of poloxamer 407 and 3%-15% per weight of poloxamer 188, 0.10 nM to 10.0 μM fluorescent nanoparticles and water or an aqueous buffer, wherein the pharmaceutical formulation is liquid at 4° C.-32° C. and forms a gel at about 37° C., their use as an in vivo marker and methods of their preparation. The inventive formulation is useful for local control and prevention of spreading/diffusion of nanoparticles, and thus allows full utilization of their quantum physics properties for example as a tool to enable surgical precision of tumor removal; even without tumor specific epitope binding antibodies.

The present invention refers to a pharmaceutical formulation for injection comprising fluorescent nanoparticles as in vivo diagnostics. The present invention relates to an injectable pharmaceutical formulation for human medicine and/or veterinary use, comprising 17% to 20% per weight of poloxamer 407 and 3%-15% per weight of poloxamer 188, 0.10 nM to 10.0 μM fluorescent nanoparticles and water or an aqueous buffer, wherein the pharmaceutical formulation is liquid at 4° C.-32° C. and forms a gel at about 37° C., their use as an in vivo marker and methods of their preparation. The inventive formulation is useful for local control and prevention of spreading/diffusion of nanoparticles, and thus allows full utilization of their quantum physics properties for example as a tool to enable surgical precision of tumor removal; even without tumor specific epitope binding antibodies.

The invention relates to water soluble crosslinkable prepolymers for the preparation of chemically stable crosslinked polymer gels, a process for preparing the same, compositions containing the same and their use such as a medical or dental filler composition.

Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound represented by the following Formula (I): where R.sup.1 is selected from hydrogen or an alkyl group having from 1 to about 16 carbon atoms; R.sup.2 is selected from a hydroxyl group, a tosylate group, an alkoxy group of the formula OR.sup.3 where R.sup.3 is selected from an alkyl group having from 1 to about 16 carbon atoms, or an ester group of the formula OCOR.sup.4, where R.sup.4 is an alkyl group having from 1 to about 16 carbon atoms, and n is from 4 to 46,000, with the proviso that when R.sup.1 is hydrogen and R.sup.2 is a hydroxy group the treatment compound has a number average molecular weight from 10,100 to 2,000,0000 g/mol.

##STR00001##

The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipation in healthy subjects. In some embodiments, the solid formulation is chewable or suckable.